Amgen Inc Patent Portfolio Statistics

Amgen Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Amgen Inc. look like?

Total Applications: 2,149
Granted Patents: 1,114
Grant Index 72.01 %
Abandoned/Rejected Applications: 433 (27.99%)
In-Process Applications: 596
Average Grant Time: 3.15 Years
Average Office Actions: 1.76

Which Technology Area Amgen Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 206
1624 Organic Chemistry 182
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 159
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 144
1626 Organic Chemistry 126

How many patents are Amgen Inc. filing every year?

Year Total Applications
2022 0*
2021 56*
2020 109
2019 89
2018 80

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Amgen Inc. in USPTO?

Publication number: US20220026442A1
Application number: 17/495,963

Abstract:
The invention provides a method for controlling contaminants in biopharmaceutical purification processes by using light scattering and UV absorbance to establish a determinant. The invention makes use of multi-angle light scattering (MALS) and UV as a continuous monitoring system to provide information about the elution peak fractions in real-time instead of conventional pooling methods that rely on a predetermined percent UV peak max value to initiate the pooling process; regardless of product quality.

Publication date: 2022-01-27
Applicant: Amgen Inc.
Inventors: Bailey Robert


Publication number:
Application number: 17/602,148

Abstract:
None

Publication date:
Applicant: Amgen Inc.
Inventors: Jimmie L Ward


Publication number: US20220017584A1
Application number: 17/494,001

Abstract:
GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

Publication date: 2022-01-20
Applicant: Amgen Inc.
Inventors: Xiong Yumei


How are Amgen Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/495,963 Method For Using Light Scattering In Real Time To Directly Monitor And Control Impurity Removal In Purification Processes 1644 Rogers, James L
17/602,148 Drug Delivery Device With Smart Grip Application Undergoing Preexam Processing
17/494,001 Growth Differentiation Factor 15 Fusion Proteins 1646
17/482,230 Kras G12C Inhibitors And Methods Of Using The Same Application Undergoing Preexam Processing 1625
17/435,768 Use Of Oncolytic Viruses For The Treatment Of Cancer Docketed New Case – Ready for Examination OPAP Central, Docket